Gateway Investment Advisers LLC Has $8.15 Million Holdings in IQVIA Holdings Inc. $IQV

Gateway Investment Advisers LLC cut its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 42.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 36,167 shares of the medical research company’s stock after selling 26,306 shares during the period. Gateway Investment Advisers LLC’s holdings in IQVIA were worth $8,152,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Claret Asset Management Corp raised its holdings in shares of IQVIA by 1.1% in the third quarter. Claret Asset Management Corp now owns 4,527 shares of the medical research company’s stock valued at $860,000 after purchasing an additional 49 shares during the last quarter. Versant Capital Management Inc raised its holdings in shares of IQVIA by 6.3% in the third quarter. Versant Capital Management Inc now owns 899 shares of the medical research company’s stock valued at $171,000 after purchasing an additional 53 shares during the last quarter. Leonard Rickey Investment Advisors P.L.L.C. raised its holdings in shares of IQVIA by 3.3% in the fourth quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 1,814 shares of the medical research company’s stock valued at $409,000 after purchasing an additional 58 shares during the last quarter. Brookstone Capital Management raised its holdings in shares of IQVIA by 2.2% in the fourth quarter. Brookstone Capital Management now owns 2,931 shares of the medical research company’s stock valued at $661,000 after purchasing an additional 63 shares during the last quarter. Finally, Private Advisor Group LLC raised its holdings in shares of IQVIA by 1.0% in the third quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock valued at $1,163,000 after purchasing an additional 63 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. UBS Group lowered their target price on shares of IQVIA from $280.00 to $240.00 and set a “buy” rating on the stock in a report on Friday, February 6th. Stifel Nicolaus lowered their target price on shares of IQVIA from $273.00 to $220.00 and set a “buy” rating on the stock in a report on Friday, February 6th. BMO Capital Markets set a $250.00 target price on shares of IQVIA in a report on Friday, February 6th. Royal Bank Of Canada assumed coverage on shares of IQVIA in a report on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 target price on the stock. Finally, Weiss Ratings downgraded shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $225.69.

IQVIA Price Performance

NYSE:IQV opened at $178.95 on Friday. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $247.04. The company has a market cap of $29.87 billion, a P/E ratio of 22.17, a P/E/G ratio of 1.75 and a beta of 1.18. The firm’s fifty day moving average price is $170.14 and its two-hundred day moving average price is $200.95. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The firm had revenue of $4.15 billion for the quarter, compared to the consensus estimate of $4.10 billion. During the same period in the previous year, the company earned $2.70 earnings per share. The company’s quarterly revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Equities analysts expect that IQVIA Holdings Inc. will post 11.5 earnings per share for the current year.

IQVIA announced that its Board of Directors has initiated a share buyback plan on Thursday, May 7th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s board believes its stock is undervalued.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.